drugset / Trial / NCT03977649

A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients

NCT03977649

Phase 4 Completed 62 enrolled Novartis Pharmaceuticals
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the effects of erenumab on central sensitization and brain networks connectivity of migraine patients

Timeline

Start
2019-07-30
Primary completion
2021-07-05
Completion
2021-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Erenumab Monoclonal antibody 140 mg Subcutaneous

Indications